Accidental Semaglutide Dosing Error Triggers Severe Angioedema in Patient with Prior ACEi Reaction
Background
The exponential rise in glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for conditions like obesity, type 2 diabetes, and cardiovascular disease has led to increased direct-to-consumer sales, often via compounding pharmacies. This surge, coupled with drug shortages, has unfortunately resulted in a rise in dosing errors and overdoses among inexperienced patients. This case highlights a rare but severe adverse drug effect, angioedema, following a semaglutide dosing error, presenting a diagnostic challenge due to the patient's history of angiotensin-converting enzyme inhibitor (ACEi)-induced angioedema.
Study Design
A 50-year-old female with a medical history including obesity (BMI 44), moderate persistent asthma, depression, and hypertension (managed with valsartan 80 mg daily) presented to the Emergency Department. She developed lip and tongue swelling approximately four hours after self-administering her first semaglutide injection. Notably, she had a history of lisinopril-induced angioedema five years prior. En route to the hospital, she received epinephrine 0.3 mg for her symptoms.
Results
The patient presented with severe lip and tongue swelling, characteristic of angioedema, which began approximately four hours after her initial semaglutide injection. The case report strongly suggests a significant dosing error was made by the inexperienced patient, leading to an accidental overdose. Her prior history of lisinopril-induced angioedema five years earlier complicated the diagnostic process, as both ACE inhibitors and, rarely, GLP-1 RAs can trigger angioedema. The immediate administration of epinephrine 0.3 mg en route to the hospital was a critical intervention. The authors emphasize the diagnostic dilemma in differentiating the cause of angioedema when multiple potential triggers, such as a new drug and a history of a known angioedema-inducing medication, are present.
The patient's presentation highlights the critical need for patient education on proper injection technique and dose titration, especially with novel self-administered therapies like semaglutide.
Key Findings
- Severe angioedema developed approximately 4 hours after a patient's first semaglutide injection.
- The angioedema was attributed to an accidental semaglutide dosing error by an inexperienced patient.
- The patient had a history of lisinopril-induced angioedema 5 years prior, complicating diagnosis.
- Initial treatment included epinephrine 0.3 mg en route to the emergency department.
Why It Matters
This case underscores the critical importance of patient education and careful instruction for individuals self-administering injectable medications like semaglutide, particularly when sourced from compounding pharmacies without direct medical oversight. For peptide users and biohackers, it highlights the potential for severe adverse events from dosing errors and the need for meticulous attention to protocol. Clinicians should be acutely aware of the rare but serious risk of angioedema with GLP-1 RAs, especially in patients with a history of ACEi-induced angioedema, as this complicates diagnosis and management. This report suggests that even a single, albeit erroneous, dose can trigger a severe reaction, emphasizing safety data and proper administration as paramount.
semaglutide
angioedema
dosing error
adverse event
case report
patient safety